MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences.
H.C. Wainwright 26th Annual Global Investment Conference | |
Date: | September 9-11, 2024 |
Location: | Lotte New York Palace Hotel |
Presentation Details: | Virtual presentation accessible online to conference attendees on the morning of Monday, September 9, 2024 |
2024 Cantor Global Healthcare Conference | |
Date: | September 17-19, 2024 |
Location: | InterContinental Barclay Hotel, New York |
Presentation Details: | Fireside chat on Wednesday, September 18 at 8:00-8:30 a.m. ET in Track 4, Empire Ballroom 1 |
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on LinkedIn and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-514-336-7800
Last Trade: | US$1.28 |
Daily Change: | -0.02 -1.54 |
Daily Volume: | 30,452 |
Market Cap: | US$58.850M |
October 10, 2024 October 09, 2024 July 10, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB